StockMarketWire.com - ImmuPharma, the specialist drug discovery and development company, revealed Thursday its Lupus drug showed positive signs of treating other autoimmune diseases in addition to Lupus.

The findings of a pre-clinical study of ImmuPharma's lupus drug, P140/Lupuzor, for chronic inflammatory demyelinating polyneuropathy, or CIPD, - an autoimmune-mediated inflammatory disease - improved the clinical and biological course of the disease, the company said.

'We are delighted that these results demonstrate positive pre-clinical data in a murine model of CIDP, which has no available disease-specific treatment. We look forward to providing a further update on the progress of our CIDP programme in due course,' Professor Sylviane Muller said.


At 9:43am: [LON:IMM] ImmuPharma PLC share price was +1.85p at 24.95p



Story provided by StockMarketWire.com